Elodie Odore1,2, François Lokiec3, Esteban Cvitkovic4,5, Mohamed Bekradda4, Patrice Herait4,5, Fabrice Bourdel4, Carmen Kahatt4, Emmanuel Raffoux6, Anastasios Stathis7, Catherine Thieblemont6, Bruno Quesnel8, David Cunningham9, Maria E Riveiro4, Keyvan Rezaï3. 1. Department of Radio-Pharmacology, Institut Curie-Hôpital René Huguenin, 35 Rue Dailly, 92210, Saint-Cloud, France. elodie.odore@curie.fr. 2. Oncology Therapeutic Development, Clichy, France. elodie.odore@curie.fr. 3. Department of Radio-Pharmacology, Institut Curie-Hôpital René Huguenin, 35 Rue Dailly, 92210, Saint-Cloud, France. 4. Oncology Therapeutic Development, Clichy, France. 5. Oncoethix GmbH, Lucerne, Switzerland. 6. Hôpital Saint Louis, Paris, France. 7. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. 8. CHRU Lille, Lille, France. 9. The Royal Marsden Hospital, London, UK.
Abstract
BACKGROUND AND OBJECTIVES: OTX015 (MK-8628) is a novel inhibitor of the bromodomain and extraterminal (BET)-bromodomain (BRD) protein family, binding specifically to bromodomains BRD2/3/4 and impacting the epigenetic regulation of several oncogenes. We characterized the pharmacokinetics of this first-in-class BET-BRD inhibitor administered as a single agent, including population pharmacokinetic modelling. METHODS: A dose-escalation, phase Ib study was performed with oral OTX015 in patients with haematologic malignancies, at doses starting from 10 mg once daily (QD) with continuous or discontinuous schedules. Five or eight blood samples were collected per patient for pharmacokinetic analysis. OTX015 plasma concentrations were determined using validated ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and analysed using a nonlinear mixed-effects modelling software program. A population pharmacokinetic model was fitted to the data, and patient demographics and clinical chemistry parameters were tested as predictive covariates on the model parameters. RESULTS: Blood samples were analysed from 81 patients treated with OTX015 at doses ranging from 10 to 160 mg QD or 40 mg twice daily (BID), and 633 time-plasma concentrations were available for analysis. A one-compartment open model with linear elimination adequately described OTX015 pharmacokinetics. The most significant covariate was lean body mass (LBM), which decreased the between-subject variability in apparent total body clearance (CL) and the volume of distribution (V). The estimated pharmacokinetic parameters were the absorption rate constant (k a) = 0.731 h(-1), V = 71.4 L and CL = 8.47 L·h(-1). CONCLUSION: The pharmacokinetics of oral OTX015 in patients with haematologic malignancies can be described with a one-compartment model. Population pharmacokinetic modelling of OTX015 plasma concentrations showed that LBM influences V and CL. These findings do not suggest the need for dose adjustment.
BACKGROUND AND OBJECTIVES: OTX015 (MK-8628) is a novel inhibitor of the bromodomain and extraterminal (BET)-bromodomain (BRD) protein family, binding specifically to bromodomains BRD2/3/4 and impacting the epigenetic regulation of several oncogenes. We characterized the pharmacokinetics of this first-in-class BET-BRD inhibitor administered as a single agent, including population pharmacokinetic modelling. METHODS: A dose-escalation, phase Ib study was performed with oral OTX015 in patients with haematologic malignancies, at doses starting from 10 mg once daily (QD) with continuous or discontinuous schedules. Five or eight blood samples were collected per patient for pharmacokinetic analysis. OTX015 plasma concentrations were determined using validated ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and analysed using a nonlinear mixed-effects modelling software program. A population pharmacokinetic model was fitted to the data, and patient demographics and clinical chemistry parameters were tested as predictive covariates on the model parameters. RESULTS: Blood samples were analysed from 81 patients treated with OTX015 at doses ranging from 10 to 160 mg QD or 40 mg twice daily (BID), and 633 time-plasma concentrations were available for analysis. A one-compartment open model with linear elimination adequately described OTX015 pharmacokinetics. The most significant covariate was lean body mass (LBM), which decreased the between-subject variability in apparent total body clearance (CL) and the volume of distribution (V). The estimated pharmacokinetic parameters were the absorption rate constant (k a) = 0.731 h(-1), V = 71.4 L and CL = 8.47 L·h(-1). CONCLUSION: The pharmacokinetics of oral OTX015 in patients with haematologic malignancies can be described with a one-compartment model. Population pharmacokinetic modelling of OTX015 plasma concentrations showed that LBM influences V and CL. These findings do not suggest the need for dose adjustment.
Authors: Jennifer A Mertz; Andrew R Conery; Barbara M Bryant; Peter Sandy; Srividya Balasubramanian; Deanna A Mele; Louise Bergeron; Robert J Sims Journal: Proc Natl Acad Sci U S A Date: 2011-09-26 Impact factor: 11.205
Authors: Takeshi Shimamura; Zhao Chen; Margaret Soucheray; Julian Carretero; Eiki Kikuchi; Jeremy H Tchaicha; Yandi Gao; Katherine A Cheng; Travis J Cohoon; Jun Qi; Esra Akbay; Alec C Kimmelman; Andrew L Kung; James E Bradner; Kwok-Kin Wong Journal: Clin Cancer Res Date: 2013-09-17 Impact factor: 12.531
Authors: Christopher J Ott; Nadja Kopp; Liat Bird; Ronald M Paranal; Jun Qi; Teresa Bowman; Scott J Rodig; Andrew L Kung; James E Bradner; David M Weinstock Journal: Blood Date: 2012-08-17 Impact factor: 22.113
Authors: Zhixiang Cheng; Yuanying Gong; Yufang Ma; Kaihua Lu; Xiang Lu; Larry A Pierce; Reid C Thompson; Susanne Muller; Stefan Knapp; Jialiang Wang Journal: Clin Cancer Res Date: 2013-02-12 Impact factor: 12.531
Authors: Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner Journal: Nature Date: 2010-09-24 Impact factor: 49.962
Authors: K Althoff; A Beckers; E Bell; M Nortmeyer; T Thor; A Sprüssel; S Lindner; K De Preter; A Florin; L C Heukamp; L Klein-Hitpass; K Astrahantseff; C Kumps; F Speleman; A Eggert; F Westermann; A Schramm; J H Schulte Journal: Oncogene Date: 2014-09-01 Impact factor: 9.867
Authors: Susu Zhang; Yue Zhao; Tiffany M Heaster; Melissa A Fischer; Kristy R Stengel; Xiaofan Zhou; Haley Ramsey; Ming-Ming Zhou; Michael R Savona; Melissa C Skala; Scott W Hiebert Journal: J Cell Biochem Date: 2018-11-11 Impact factor: 4.429
Authors: Xuguang Zhu; Keisuke Enomoto; Li Zhao; Yuelin J Zhu; Mark C Willingham; Paul Meltzer; Jun Qi; Sheue-Yann Cheng Journal: Clin Cancer Res Date: 2016-07-20 Impact factor: 12.531
Authors: M Anjanappa; Y Hao; E R Simpson; P Bhat-Nakshatri; J B Nelson; S A Tersey; R G Mirmira; A A Cohen-Gadol; M R Saadatzadeh; L Li; F Fang; K P Nephew; K D Miller; Y Liu; H Nakshatri Journal: Oncogene Date: 2017-09-11 Impact factor: 9.867
Authors: Hae In Choi; Ga Yeong An; Mina Baek; Eunyoung Yoo; Jin Choul Chai; Young Seek Lee; Kyoung Hwa Jung; Young Gyu Chai Journal: Sci Rep Date: 2021-06-03 Impact factor: 4.379
Authors: Laura Molenaar-Kuijsten; Bart Albertus Wilhelmus Jacobs; Sophie Alberdine Kurk; Anne Maria May; Thomas Petrus Catharina Dorlo; Jacob Hendrik Beijnen; Neeltje Steeghs; Alwin Dagmar Redmar Huitema Journal: Cancer Med Date: 2021-06-14 Impact factor: 4.452